ERBB2 and gastroesophageal junction adenocarcinoma: Therefore, in accordance with the Japanese EAP system, a multicenter, open-label, expanded-access study was conducted for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma between March 25 and September 25, 2020, prior to marketing approval in Japan.